Shares of other companies:
April 29, 2024 Tesla, Baidu Join Forces for Self-Driving Tech in China
April 27, 2024 Alphabet and Microsoft’s AI Investments Yield Strong Returns
April 26, 2024 Top 10 High Dividend Yield Stocks
Tesla Q1: Facing A Liquidity Crunch; Dilution Ahead?
April 29, 2024
Tesla Q1: Model 2 Could Be Their Model T
April 25, 2024
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
April 12, 2024 Improve Your Financial Status: A How-To Guide
Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade
Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
MRNA Stock News and Mentions of Moderna, Inc. Stocktwits
Updated: April 30, 2024 (09:46)
Sector: Healthcare
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 60 days where Moderna Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of Moderna, Inc. (MRNA).
You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the Moderna stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles
News and Mentions of Moderna, Inc. (MRNA)
April 29, 2024 (15:33) / "Zacks Commentary" (by Zacks Equity Research)
Moderna ( MRNA ) Gears Up for Q1 Earnings: Here's What to Expect
Investors' focus will likely be on updates on Moderna's (MRNA) expected RSV vaccine launch and its late-stage pipeline candidates when it reports first-quarter earnings.
In Article Trend: Neutral
April 29, 2024 (14:02) / "Benzinga" (by Upwallstreet)
mRNA Is Promising A Breakthrough In Fighting Cancer - Pfizer ( NYSE:PFE )
When it comes to cancer, there's innovation both on the diagnostics and the treatment front thanks to messenger RNA, or mRNA, a genetic material we all got acquainted with during the COVID-19 era as it allowed pharmaceutical companies like Pfizer Inc PFE and Moderna Inc MRNA to develop their ...
In Article Trend: Neutral
April 29, 2024 (13:16) / "Zacks Commentary" (by Zacks Equity Research)
Unveiling Moderna ( MRNA ) Q1 Outlook: Wall Street Estimates for Key Metrics
Beyond analysts' top -and-bottom-line estimates for Moderna (MRNA), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.
In Article Trend: Neutral
April 29, 2024 (12:10) / "Motley Fool" (by Prosper Junior Bakiny)
3 Beaten-Down Stocks I Wouldn't Touch With a 10-Foot Pole
These stocks aren't bargains.
In Article Trend: Neutral
April 29, 2024 (09:10) / "Motley Fool" (by Adria Cimino)
Nasdaq Bull Market: Here's the Best Investing Move You Can Make Right Now
Many technology stocks are soaring, and you may be wondering if they've gotten too expensive.
In Article Trend: Somewhat-Bullish
April 29, 2024 (08:28) / "Barrons" (by Joe Woelfel)
Tesla, Alphabet, SoFi, Paramount, Apple, Domino's, and More Stock Market Movers
Tesla, Alphabet, Fulton Financial, SoFi, Apple, Amazon, and More Stock Market Movers ...
In Article Trend: Neutral
April 29, 2024 (05:51) / "Benzinga" (by Shanthi Rexaline)
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week - Invesco QQQ Trust, Series 1 ( NASDAQ:QQQ ) , SPDR S&P 500 ( ARCA:SPY )
Corporate earnings came to the market's rescue in the past week, helping to overcome rate fears. As we look ahead to the unfolding week, it remains to be seen whether the tech earnings deluge can keep the rally's momentum going.
In Article Trend: Somewhat-Bullish
April 28, 2024 (20:00) / "Barrons" (by Nicholas Jasinski)
Apple and Amazon Earnings, the Fed, Jobs Data, and More to Watch
Apple and Amazon Earnings, Fed Rate Decision, Jobs Data, and More to Watch This Week ...
In Article Trend: Neutral
April 28, 2024 (12:45) / "Motley Fool" (by Rachel Warren)
2 Top Growth Stocks to Buy Right Now and Hold Forever
These healthcare stocks can provide enviable long-term portfolio growth.
In Article Trend: Somewhat-Bullish
April 26, 2024 (22:00) / "Zacks Commentary" (by Zacks Equity Research)
Moderna ( MRNA ) Surpasses Market Returns: Some Facts Worth Knowing
Moderna (MRNA) closed the most recent trading day at $107.97, moving +1.69% from the previous trading session.
In Article Trend: Somewhat-Bullish
April 26, 2024 (14:00) / "Zacks Commentary" (by Zacks Equity Research)
Arvinas, Inc. ( ARVN ) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Arvinas (ARVN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In Article Trend: Somewhat-Bullish
April 26, 2024 (08:50) / "Motley Fool" (by Adria Cimino)
Should You Buy Moderna Before May 12?
This ambitious biotech aims to launch 15 products over the coming five years.
In Article Trend: Somewhat-Bullish
April 25, 2024 (19:30) / "Motley Fool" (by Motley Fool Transcribing)
Merck ( MRK ) Q1 2024 Earnings Call Transcript
MRK earnings call for the period ending March 31, 2024.
In Article Trend: Somewhat-Bullish
April 25, 2024 (18:10) / "PR Newswire" (by Kong Inc.)
Sunil Wadhwa Joins Kong as Chief Customer Officer
SAN FRANCISCO, April 25, 2024 /PRNewswire/ -- Kong Inc., a leading developer of cloud API technologies, today welcomed Sunil Wadhwa as Chief Customer Officer.
In Article Trend: Bullish
April 25, 2024 (17:51) / "Benzinga" (by Vandana Singh)
What's Going On With Pfizer Stock On Thursday? - GSK ( NYSE:GSK ) , Pfizer ( NYSE:PFE )
GSK Plc GSK has reportedly taken legal action against Pfizer Inc PFE and BioNTech SE BNTX in a Delaware federal court, alleging patent infringement concerning mRNA technology used in the COVID-19 vaccines. The lawsuit contends that Pfizer and BioNTech's Comirnaty vaccines violate GSK's patents.
In Article Trend: Neutral
)
April 25, 2024 (15:18) / "Business Standard" (by Reuters)
GlaxoSmithKline sues Pfizer, BioNTech over Covid-19 vaccine technology
GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA ( mRNA ) technology in the companies' blockbuster COVID-19 vaccines.
In Article Trend: Somewhat-Bearish
April 25, 2024 (14:02) / "Zacks Commentary" (by Zacks Equity Research)
Analysts Estimate Moderna ( MRNA ) to Report a Decline in Earnings: What to Look Out for
Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In Article Trend: Neutral
April 25, 2024 (13:45) / "Benzinga" (by Benzinga Insights)
How Is The Market Feeling About Moderna? - Moderna ( NASDAQ:MRNA )
Moderna's MRNA short percent of float has fallen 3.53% since its last report. The company recently reported that it has 21.44 million shares sold short, which is 7.38% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.3 days to cover their ...
In Article Trend: Somewhat-Bullish
April 25, 2024 (10:32) / "CNBC" (by Annika Kim Constantino)
Merck beats earnings expectations, raises outlook on strong Keytruda and vaccine sales
The first-quarter results come as Merck shows substantial progress in preparing for Keytruda's patent expiration in 2028.
In Article Trend: Neutral
April 24, 2024 (13:34) / "Benzinga" (by Adam Eckert)
Moderna Stock Jumps On Collaboration With OpenAI: What's Going On? - Moderna ( NASDAQ:MRNA )
Moderna Inc MRNA shares are trading higher Wednesday after the company announced an ongoing collaboration with OpenAI. What To Know: Moderna said the company and Microsoft Corp MSFT-backed OpenAI share a vision of AI's transformative potential in the future of business and healthcare.
In Article Trend: Somewhat-Bullish
April 23, 2024 (20:56) / "Forbes" (by Jim Euchner)
Do You ( Really ) Need A Chief Artificial Intelligence Officer?
AI is changing business profoundly and quickly. It is enabling new business models, making existing business models radically more efficient, and creating the potential for products conceived in entirely new ways. It is also making individual contributors more productive at day-to-day tasks, from ...
In Article Trend: Somewhat-Bullish
April 23, 2024 (19:00) / "Benzinga" (by Vandana Singh)
Moderna Faces Pfizer, BioNTech in London Patent Battle over Covid-19 Vaccines In Legal Showdown - Moderna ( NASDAQ:MRNA ) , Pfizer ( NYSE:PFE ) , BioNTech ( NASDAQ:BNTX )
Moderna Inc. MRNA is set to clash with Pfizer Inc. PFE and BioNTech SE BNTX in a pivotal London patent trial concerning the development of COVID-19 vaccines. The High Court is slated to address a legal complaint brought by Moderna.
In Article Trend: Neutral
April 23, 2024 (10:20) / "Zacks Commentary" (by Zacks Equity Research)
Is First Trust NASDAQ-100 Equal Weighted ETF ( QQEW ) a Strong ETF Right Now?
Smart Beta ETF report for ...
In Article Trend: Somewhat-Bullish
April 23, 2024 (10:20) / "Zacks Commentary" (by Zacks Equity Research)
Is SPDR S&P Biotech ETF ( XBI ) a Strong ETF Right Now?
Smart Beta ETF report for ...
In Article Trend: Somewhat-Bullish
April 22, 2024 (18:39) / "Zacks Commentary" (by Zacks Equity Research)
How Should You Play Merck ( MRK ) Stock Ahead of Q1 Earnings?
Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports first-quarter 2024 earnings.
In Article Trend: Somewhat-Bullish
April 22, 2024 (17:02) / "Benzinga" (by Benzinga Insights)
Moderna Options Trading: A Deep Dive into Market Sentiment - Moderna ( NASDAQ:MRNA )
Whales with a lot of money to spend have taken a noticeably bullish stance on Moderna. Looking at options history for Moderna MRNA we detected 10 trades. If we consider the specifics of each trade, it is accurate to state that 70% of the investors opened trades with bullish expectations and 30% ...
In Article Trend: Somewhat-Bullish
April 19, 2024 (21:50) / "Zacks Commentary" (by Zacks Equity Research)
Moderna ( MRNA ) Stock Moves -0.58%: What You Should Know
Moderna (MRNA) reachead $101.41 at the closing of the latest trading day, reflecting a -0.58% change compared to its last close.
In Article Trend: Neutral
April 18, 2024 (18:00) / "Motley Fool" (by Motley Fool Transcribing)
Blackstone ( BX ) Q1 2024 Earnings Call Transcript
BX earnings call for the period ending March 31, 2024.
In Article Trend: Somewhat-Bullish
April 17, 2024 (22:00) / "Zacks Commentary" (by Zacks Equity Research)
Moderna ( MRNA ) Stock Moves -0.34%: What You Should Know
In the latest trading session, Moderna (MRNA) closed at $103.44, marking a -0.34% move from the previous day.
In Article Trend: Neutral
April 17, 2024 (14:18) / "Benzinga" (by Benzinga Insights)
Moderna Options Trading: A Deep Dive into Market Sentiment - Moderna ( NASDAQ:MRNA )
High-rolling investors have positioned themselves bearish on Moderna MRNA, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking of publicly available options data.
In Article Trend: Somewhat-Bullish
April 16, 2024 (15:49) / "Benzinga" (by Upwallstreet)
Johnson & Johnson Shows Focus On Strengthening Its Business Upon Its Consumer Health Unit Spinoff - Johnson & Johnson ( NYSE:JNJ )
On Tuesday, Johnson & Johnson JNJ delivered a rather mixed first quarter report. Adjusted earnings surpassed estimates as sales in its medical devices business surged, while revenue was almost in line with estimates.
In Article Trend: Neutral
April 16, 2024 (13:00) / "Zacks Commentary" (by Zacks Equity Research)
Moderna, Inc. ( MRNA ) is Attracting Investor Attention: Here is What You Should Know
Moderna (MRNA) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
In Article Trend: Somewhat-Bullish
April 16, 2024 (08:55) / "Motley Fool" (by Adria Cimino)
2 Artificial Intelligence ( AI ) in Healthcare Stocks to Buy and Hold for Great Long-Term Potential
These companies have gotten in on AI early and could emerge as winners.
In Article Trend: Bullish
April 15, 2024 (12:00) / "PR Newswire"
Viatris Appoints Corinne Le Goff as Chief Commercial Officer - PR Newswire
Viatris Appoints Corinne Le Goff as Chief Commercial Officer PR ...
In Article Trend: Somewhat-Bullish
April 15, 2024 (10:00) / "Benzinga" (by Globe Newswire)
Shah Capital nominates two highly qualified independent director candidates for Novavax - Novavax ( NASDAQ:NVAX )
RALEIGH, N.C., April 15, 2024 ( GLOBE NEWSWIRE ) -- Shah Capital, which owns approximately 6.7% of the outstanding common stock of Novavax NVAX, has today issued the below statement:
In Article Trend: Somewhat-Bullish
)
April 15, 2024 (05:20) / "Business Standard" (by Reuters)
US-based Hedge fund Shah Capital urges Novavax board shake-up: Report
US-based hedge fund Shah Capital wrote to the Novavax board on Monday to push for the instalment of two new independent directors, the Financial Times reported on Monday.
In Article Trend: Somewhat-Bearish
April 14, 2024 (09:55) / "Motley Fool" (by Adria Cimino and Keith Speights)
2 Stocks Down 30% to Buy Right Now
These stocks have plenty of catalysts ahead.
In Article Trend: Somewhat-Bullish
April 12, 2024 (13:22) / "Zacks Commentary" (by Zacks Equity Research)
The Zacks Analyst Blog Highlights Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals
Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals are part of the Zacks top Analyst Blog.
In Article Trend: Somewhat-Bullish
April 12, 2024 (13:13) / "Benzinga" (by Caleb Naysmith)
Bill Gates Called For A 'Universal Flu Vaccine,' Now The CDC Director Says The Organization Is 'Activated' After Issuing Bird Flu Alert - CureVac ( NASDAQ:CVAC ) , BioNTech ( NASDAQ:BNTX )
Bill Gates warned about the risk of pandemics well before COVID-19. In 2018, he predicted that "there is a significant probability of a large and lethal, modern-day pandemic occurring in our lifetimes" because of "the continual emergence of new pathogens, the increasing risk of a bioterror attack ...
In Article Trend: Somewhat-Bearish
April 12, 2024 (12:45) / "Motley Fool" (by Alex Carchidi)
1 New Green Flag for Moderna and Merck Stock
There's a new reason to believe that their joint projects are going well.
In Article Trend: Neutral
April 12, 2024 (10:35) / "Motley Fool" (by David Jagielski)
Down 60% From Its 52-Week High, Is Novavax Stock a Buy?
Is there still too much risk surrounding this business?
In Article Trend: Neutral
April 11, 2024 (22:00) / "Zacks Commentary" (by Zacks Equity Research)
Moderna ( MRNA ) Stock Dips While Market Gains: Key Facts
Moderna (MRNA) closed the most recent trading day at $107.01, moving -0.12% from the previous trading session.
In Article Trend: Neutral
April 11, 2024 (21:30) / "Benzinga" (by Benzinga Insights)
$1000 Invested In Moderna 5 Years Ago Would Be Worth This Much Today - Moderna ( NASDAQ:MRNA )
Moderna MRNA has outperformed the market over the past 5 years by 22.81% on an annualized basis producing an average annual return of 35.1%. Currently, Moderna has a market capitalization of $40.98 billion.
In Article Trend: Somewhat-Bullish
April 11, 2024 (20:21) / "Forbes" (by Ty Roush)
CDC Finds No Link Between COVID Vaccines And Cardiac Death In Young People
There is no evidence to suggest COVID vaccines could cause sudden cardiac death and other heart problems in young people, the Centers for Disease Control and Prevention said Thursday, following a string of unfounded conspiracy theories in recent years linking the vaccines to cardiac arrest in ...
In Article Trend: Somewhat-Bearish
April 11, 2024 (16:16) / "CNBC" (by Annika Kim Constantino)
Moderna halts plans to build Kenya vaccine plant as Covid shot demand plunges
Moderna's decision aligns with its broader effort to cut costs by resizing its Covid vaccine manufacturing footprint.
In Article Trend: Neutral
April 11, 2024 (15:24) / "Benzinga" (by Vandana Singh)
Declining COVID-19 Vaccine Sales Pinches Moderna, Pauses Kenya Vaccine Plant Plans - Moderna ( NASDAQ:MRNA )
Famed COVID-19 vaccine maker Moderna Inc MRNA has decided to pause its plans to construct a vaccine manufacturing plant in Kenya, signaling a shift away from investing in pandemic preparedness in Africa as demand for COVID-19 vaccines wanes.
In Article Trend: Neutral
April 11, 2024 (13:12) / "Zacks Commentary" (by Zacks Equity Research)
Will Novavax's ( NVAX ) Strategic Reshaping Curb Cash Burn?
To extend its existing cash runway and curb cash burn, Novavax (NVAX) initiates multiple restructuring initiatives that are aimed at lowering operating expenses and enhancing profitability.
In Article Trend: Neutral
April 11, 2024 (10:45) / "Benzinga" (by Zacks)
Moderna ( MRNA ) Up 6% on Upbeat Data From Cancer Jab Study - ADMA Biologics ( NASDAQ:ADMA ) , ANI Pharmaceuticals ( NASDAQ:ANIP )
Shares of Moderna MRNA rose 6.2% on Apr 9 after management announced encouraging data from a portion of an early-stage study on mRNA-4157/V940, its investigational individualized neoantigen therapy, in certain patients with head and neck cancer. The INT is being developed in collaboration with ...
In Article Trend: Somewhat-Bullish
April 10, 2024 (20:15) / "Benzinga" (by Benzinga Insights)
A Closer Look at Moderna's Options Market Dynamics - Moderna ( NASDAQ:MRNA )
Investors with a lot of money to spend have taken a bearish stance on Moderna MRNA. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.
In Article Trend: Somewhat-Bullish
April 10, 2024 (17:19) / "Zacks Commentary" (by Zacks Equity Research)
Biotech Stock Roundup: MRNA Up on Vaccine Data, BMY's Updates & More News
Moderna (MRNA) and Bristol Myers (BMY) are in focus on pipeline and regulatory updates.
In Article Trend: Somewhat-Bullish
April 10, 2024 (14:59) / "Zacks Commentary" (by Zacks Equity Research)
Moderna ( MRNA ) Up 6% on Upbeat Data From Cancer Jab Study
Data from an early-stage study shows that treatment with Moderna's (MRNA) experimental cancer therapy achieved positive clinical response in patients with a specific type of head and neck cancer.
In Article Trend: Neutral
April 10, 2024 (14:47) / "Benzinga" (by Upwallstreet)
The Pharmaceutical Industry Finds Itself At A Historical Crossroads - Bristol-Myers Squibb ( NYSE:BMY )
Bristol Myers Squibb BMY, Merck & Co Inc MRK, Pfizer Inc PFE and Johnson & JohnsonJNJ are facing the so-called patent cliffs which imply revenue of tens of billions of dollars between now and and the end of this decade is at risk.
In Article Trend: Neutral
April 10, 2024 (13:26) / "Zacks Commentary" (by Zacks Equity Research)
Pfizer's ( PFE ) RSV Vaccine Study in Adults Under 60 Meets Goal
Pfizer's (PFE) RSV vaccine, Abrysvo, generates an immune response in a phase III study evaluating it in higher-risk adults aged 18 to 59, non-inferior to that in older adults.
In Article Trend: Somewhat-Bullish
April 10, 2024 (13:25) / "Zacks Commentary" (by Zacks Equity Research)
Company News for Apr 10, 2024
Companies in The News Are: MRNA, MRK, COIN, BN, ...
In Article Trend: Somewhat-Bullish
April 10, 2024 (10:40) / "Zacks Commentary" (by Zacks Equity Research)
Moderna ( MRNA ) Surges 6.2%: Is This an Indication of Further Gains?
Moderna (MRNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
In Article Trend: Somewhat-Bullish
April 10, 2024 (03:15) / "Business Standard" (by Capital Market)
US: Stocks little changed ahead of CPI data
The March consumer price index report is slated for release Wednesday. Investors will also see the release of the minutes of the Fed's latest monetary policy meeting on Wednesday, which could also shed additional light on officials' thinking on rates.
In Article Trend: Neutral
April 9, 2024 (23:55) / "Money Control"
US stocks inch to higher close as markets brace for CPI data, earnings
The tech-heavy Nasdaq Composite Index, boosted by chips, enjoyed a more substantial advance, with the SP 500 nominally higher.
In Article Trend: Neutral
April 9, 2024 (20:10) / "Barrons" (by Barron's Automation)
U.S. Indexes Ended Tuesday Mixed As UWM Holdings Led, Vistra Lagged
Stock indexes in the U.S. finished mixed Tuesday as the NASDAQ Composite Index added 0.32%. Meanwhile, the S&P 500 Index increased 0.14%, and the Dow fell 0.02%. Small-cap stocks, as per the Russell 2000 Index, rose 0.27%, and the Cboe Volatility Index was up 0.79%.
In Article Trend: Neutral
April 9, 2024 (18:29) / "Business Insider" (by Piero Cingari)
Stocks Fall Ahead Of Key Inflation Data, Gold Defends Record Highs; Bitcoin Stumbles Below $70,000: What's Driving Markets Tuesday?
Stocks Fall Ahead Of Key Inflation Data, Gold Defends Record Highs. Bitcoin Stumbles Below $70000: What's Driving ... - Markets Insider ...
In Article Trend: Neutral
April 9, 2024 (18:16) / "Benzinga" (by Vandana Singh)
Why Is Moderna Stock Trading Higher Today? - Moderna ( NASDAQ:MRNA )
Moderna Inc MRNA stock surged on Tuesday after the company shared the AACR 2024 annual meeting poster presentation of mRNA-4157 ( V940 ) individualized neoantigen therapy plus Merck & Co Inc's MRK Keytruda ( pembrolizumab ) in advanced unresectable HPV-negative head and neck carcinoma.
In Article Trend: Somewhat-Bullish
April 9, 2024 (14:43) / "Benzinga" (by Avi Kapoor)
BlackBerry, Nurix Therapeutics, Tesla And Other Big Stocks Moving Higher On Tuesday - BlackBerry ( NYSE:BB ) , Tesla ( NASDAQ:TSLA )
U.S. stocks were lower, with the Dow Jones index falling over 200 points on Tuesday. Shares of BlackBerry Limited BB rose sharply during Tuesday's session. The company announced a collaboration with Advanced Micro Devices, Inc.
In Article Trend: Neutral
April 9, 2024 (10:35) / "Motley Fool" (by Adria Cimino)
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.
These companies are close to launching new products that could supercharge revenue.
In Article Trend: Somewhat-Bullish
April 9, 2024 (08:50) / "Motley Fool" (by Adria Cimino)
Bull Market and Beyond: 3 Stocks Just Waiting to Soar
These stocks, a bargain today, are players to hold on to for the long term.
In Article Trend: Bullish
April 8, 2024 (12:00) / "PR Newswire"
Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences - PR Newswire
Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences PR ...
In Article Trend: Bullish
April 8, 2024 (08:02) / "PR Newswire" (by HAVIT)
Los innovadores productos de audio de HAVIT brillan en ferias comerciales internacionales de electrónica
HONG KONG, 8 de abril de 2024 /PRNewswire/ -- En 2024, se llevarán a cabo una serie de ferias comerciales internacionales de electrónica, incluidas Global Sources Consumer Electronics Show, Hong Kong Electronics Fair, la 135ª Feria de Cantón, ICTCOMM VIETNAM 2024, COMPUTEX TAIPEI, GITEX Africa ...
In Article Trend: Neutral
April 5, 2024 (18:26) / "Benzinga" (by Tornado)
Moderna's Vaccines Day 2024: A Glimpse into the Future of Infectious Disease Prevention - Moderna ( NASDAQ:MRNA )
Moderna, Inc. MRNA recently hosted its fourth annual Vaccines Day, offering a deep dive into the company's expanding infectious disease vaccines portfolio.
In Article Trend: Somewhat-Bullish
April 4, 2024 (18:32) / "Benzinga" (by Vandana Singh)
Arbutus Vs. Moderna Patent Dispute Set for Continuing Discovery - Arbutus Biopharma ( NASDAQ:ABUS ) , Moderna ( NASDAQ:MRNA )
A Delaware District Court sided with Arbutus Biopharma Corporation ABUS and Genevant Sciences in their ongoing patent infringement case against Moderna Inc MRNA COVID-19 vaccine. The companies jointly submitted a claim construction brief to the Delaware district court, seeking clarification on ...
In Article Trend: Neutral
April 4, 2024 (16:30) / "GlobeNewswire" (by GeoVax)
GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine
Presentation Made During the 24th Annual World Vaccine Congress ...
In Article Trend: Neutral
April 4, 2024 (16:30) / "Benzinga" (by Globe Newswire)
GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine - Geovax Labs ( NASDAQ:GOVXW ) , Geovax Labs ( NASDAQ:GOVX )
Presentation Made During the 24th Annual World Vaccine Congress ATLANTA, GA, April 04, 2024 ( GLOBE NEWSWIRE ) -- via NewMediaWire -- GeoVax Labs, Inc.
In Article Trend: Neutral
April 4, 2024 (13:34) / "Benzinga" (by Surbhi Jain)
Moderna Shares Slip Over Covid Vaccine Patent Dispute, But Chart Signals Potential Rebound Ahead Moderna Shares Slip Over Covid Vaccine Patent Dispute, But Is Chart About To Form A Golden Cross? - Moderna ( NASDAQ:MRNA )
Moderna Inc MRNA stock closed lower by 2.32% on Wednesday, as news around Arbutus Biopharma ABUS impacted investor sentiment. Arbutus has received permission to pursue its patent infringement complaint against Moderna. The claim involves the messenger-RNA technology used in Moderna's Covid vaccine.
In Article Trend: Somewhat-Bullish
April 4, 2024 (12:30) / "GlobeNewswire" (by Arbutus Biopharma Corporation)
Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna
WARMINSTER, Pa., April 04, 2024 ( GLOBE NEWSWIRE ) -- Arbutus Biopharma Corporation ( Nasdaq: ABUS ) , a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus ( cHBV ) infection, today issued ...
In Article Trend: Neutral
April 3, 2024 (12:50) / "Zacks Commentary" (by Zacks Equity Research)
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
In Article Trend: Somewhat-Bullish
April 3, 2024 (12:00) / "GlobeNewswire" (by CytomX Therapeutics Inc.)
CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific ( TCB ) Collaboration with Astellas
- Achievement of latest clinical candidate triggers additional $5 million milestone payment to CytomX and is the third milestone achieved in the collaboration to date ...
In Article Trend: Neutral
April 2, 2024 (14:17) / "Benzinga" (by Upwallstreet)
Pharma's Post-Pandemic Story To Unlock A Cancer-Free Era - Pfizer ( NYSE:PFE )
Pfizer PFE and Moderna MRNA did not only earn billions of dollars from their COVID-19 leading products but also rose to fame for saving the world from an unforeseen pandemic. But, in a post-pandemic world, Pfizer and Moderna shares lost about 30% of their respective value over the past year.
In Article Trend: Neutral
April 2, 2024 (14:15) / "Motley Fool" (by Prosper Junior Bakiny)
1 Beaten-Down Stock to Buy and 1 to Avoid Like the Plague
These stocks could move in very different directions over the long run.
In Article Trend: Somewhat-Bullish
April 2, 2024 (12:50) / "Zacks Commentary" (by Zacks Equity Research)
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
In Article Trend: Bullish
April 1, 2024 (21:50) / "Zacks Commentary" (by Zacks Equity Research)
Why Moderna ( MRNA ) Dipped More Than Broader Market Today
Moderna (MRNA) reachead $105.60 at the closing of the latest trading day, reflecting a -0.9% change compared to its last close.
In Article Trend: Somewhat-Bullish
April 1, 2024 (19:52) / "Motley Fool" (by Eric Volkman)
Is Moderna Stock Going to $214? 1 Wall Street Analyst Thinks So.
Moderna, famous for its coronavirus vaccine, is only at the start of a trip skyward, a market professional believes.
In Article Trend: Somewhat-Bullish
April 1, 2024 (14:15) / "Motley Fool" (by Prosper Junior Bakiny)
2 Stocks Down 30% and 27% to Buy and Hold
Look beyond these companies' challenges.
In Article Trend: Somewhat-Bullish
April 1, 2024 (13:29) / "CNN" (by Eva Rothenberg)
US scientists are leaving academia. That's bad news for drug companies | Business
US scientists are leaving academia. That's bad news for drug companies ...
In Article Trend: Neutral
April 1, 2024 (12:45) / "Motley Fool" (by Jeff Santoro)
Moderna Stock: Buy, Sell, or Hold?
Moderna is more than its COVID-19 vaccine, but risks for investors still exist.
In Article Trend: Neutral
April 1, 2024 (12:35) / "PR Newswire" (by Carisma Therapeutics Inc.)
Carisma Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Company to prioritize CT-0525 as its anti-HER2 CAR-M product candidate and will cease further development of CT-0508 Other prioritized pipeline programs include the Company's in vivo CAR-M collaboration with Moderna, and research programs including fibrosis
In Article Trend: Somewhat-Bullish
April 1, 2024 (09:22) / "Zacks Commentary" (by Zacks Equity Research)
Stock Market News for Apr 1, 2024
U.S. stock markets closed mixed on Thursday to end a fascinating first quarter of 2024.
In Article Trend: Neutral
April 1, 2024 (09:05) / "Motley Fool" (by Adria Cimino)
Better Recovery Story Buy: Pfizer vs Moderna
Pfizer and Moderna each have slipped about 30% over the past year.
In Article Trend: Somewhat-Bullish
March 29, 2024 (19:55) / "PR Newswire"
XCMG Machinery triunfa con el German Design Award 2024 por sus destacadas campañas integradas y publicidad - PR Newswire
XCMG Machinery triunfa con el German Design Award 2024 por sus destacadas campañas integradas y publicidad PR ...
In Article Trend: Neutral
March 29, 2024 (15:30) / "Zacks Commentary" (by Zacks Equity Research)
Why Is Editas ( EDIT ) Down 26.2% Since Last Earnings Report?
Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
In Article Trend: Neutral
March 29, 2024 (10:01) / "South China Morning Post" (by Daniel Ren)
Shanghai's US$13.8 billion fund of funds to boost AI, semiconductor firms
Mainland China's commercial and financial hub plans to set up a 100 billion yuan (US$13.8 billion) fund of funds focusing on key technology sectors to fire up the local economy.
In Article Trend: Somewhat-Bullish
March 28, 2024 (15:38) / "Zacks Commentary" (by Zacks Equity Research)
Moderna ( MRNA ) Posts Pipeline Progress, Secures Blackstone Funding
Moderna (MRNA) posts data on three experimental vaccines and intends to advance them to late-stage studies. It also secures $750 million in funding from Blackstone to advance its influenza program.
In Article Trend: Neutral
March 28, 2024 (15:30) / "Zacks Commentary" (by Zacks Equity Research)
Apellis Pharmaceuticals ( APLS ) Down 8.7% Since Last Earnings Report: Can It Rebound?
Apellis Pharmaceuticals (APLS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
In Article Trend: Neutral
March 28, 2024 (12:33) / "Zacks Commentary" (by Ekta Bagri)
Biotech Stock Roundup: PRAX, VKTX Up on Study Results & MRNA, REGN Give Updates
Praxis Precision Medicines, Inc. (PRAX) and Viking Therapeutics, Inc. (VKTX) gain from positive study updates.
In Article Trend: Neutral
March 28, 2024 (12:30) / "Motley Fool" (by Marc Rapport)
Bull Market Buys: 3 Dividend Stocks to Own for the Long Run
Invest in stability, dividends, and growth with these three accomplished real estate operators.
In Article Trend: Bullish
March 28, 2024 (09:55) / "Motley Fool" (by Adria Cimino)
Better Cathie Wood Stock: Moderna vs. Intellia
Moderna and Intellia have declined in the double digits over the past year.
In Article Trend: Somewhat-Bullish
March 27, 2024 (16:24) / "Zacks Commentary" (by Zacks Equity Research)
Moderna ( MRNA ) Posts Upbeat Data From Next-Gen COVID Jab Study
Data from a late-stage study shows that Moderna's (MRNA) next-generation COVID vaccine induces a more robust immune response compared with its previously approved bivalent COVID vaccine.
In Article Trend: Neutral
March 27, 2024 (15:30) / "Zacks Commentary" (by Zacks Equity Research)
Why Is Rocket Pharmaceuticals ( RCKT ) Down 13.6% Since Last Earnings Report?
Rocket Pharmaceuticals (RCKT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
In Article Trend: Neutral
March 27, 2024 (12:51) / "Benzinga" (by Adam Eckert)
What's Going On With Moderna Stock Wednesday? - Moderna ( NASDAQ:MRNA )
Moderna Inc MRNA shares are trading higher Wednesday after the company announced that MRNA-1283 met the primary endpoints in its Phase 3 clinical trial. Additionally, Blackstone Life Sciences announced an investment to support the company's influenza program.
In Article Trend: Somewhat-Bullish
March 27, 2024 (12:46) / "CNBC" (by Annika Kim Constantino)
Moderna moves three vaccines into final stage trials as it works to rebound from Covid slump
Moderna will chart its post-Covid future Wednesday during its fifth annual "Vaccines Day," an investor event in Boston.
In Article Trend: Neutral
March 27, 2024 (11:20) / "Business Standard" (by Reuters)
Moderna secures $750 mn from Blackstone Life Sciences to develop flu shots
Moderna said on Wednesday it has entered into an agreement with private equity firm Blackstone's life science investment platform for a funding of $750 million to develop its mRNA flu vaccines.
In Article Trend: Neutral
March 27, 2024 (02:30) / "Benzinga" (by Benzinga Neuro)
Cathie Wood's Ark Invest Continues To Double Down On Moderna, Sells Nvidia Shares - Moderna ( NASDAQ:MRNA )
On Tuesday, Cathie Wood's Ark Invest made a significant move by increasing its stake in Moderna Inc. MRNA, a leading COVID-19 vaccine maker. This move comes amidst a series of upcoming catalysts for the biotech firm. Ark Invest, through its flagship Ark Innovation ETF ARKK, purchased a whopping ...
In Article Trend: Bullish
March 26, 2024 (22:47) / "CNN" (by By Andrew Menezes and Isabelle D'Antonio)
Shanahan shares details of growing up in Oakland in first remarks as VP candidate
2024 election live updates: RFK Jr. vice president announcement ...
In Article Trend: Neutral
March 26, 2024 (21:17) / "CNN" (by CNN)
Meanwhile: Trump is selling Bibles for $59.99 as he faces growing legal bills
2024 election live updates: RFK Jr. vice president announcement ...
In Article Trend: Neutral
March 26, 2024 (21:17) / "Investors Business Daily" (by Investor's Business Daily)
Is This Merck's Next Big Billions-Of-Dollars Act After Keytruda?
Merck Stock: Is The Cardiovascular Renaissance Here With Sotatercept Approval? Investor's Business Daily ...
In Article Trend: Neutral
March 26, 2024 (19:32) / "CNN" (by Gregory Krieg)
Who is Nicole Shanahan, Robert F. Kennedy Jr.'s vice presidential pick? | Politics
Who is Nicole Shanahan, Robert F. Kennedy Jr.'s vice presidential pick? ...
In Article Trend: Neutral
March 26, 2024 (18:38) / "Benzinga" (by PRNewswire)
Academy Award® Winner Matthew McConaughey Narrates MacGillivray Freeman's 3D Documentary for IMAX® and Giant Screen Theaters "Superhuman Body: World of Medical Marvels"
Giant screen film celebrates the wonders of the human body and the scientific breakthroughs that are transforming human health when it opens in select theatres starting April 12
In Article Trend: Bullish
March 26, 2024 (16:39) / "Benzinga" (by Vandana Singh)
Moderna's Next Gen COVID Vaccine Meets Primary Goal In Late-Stage Trial - Moderna ( NASDAQ:MRNA )
Tuesday, Moderna Inc MRNA said that mRNA-1283, the company's next-generation COVID-19 vaccine, has met the primary endpoints of its Phase 3 trial. The data demonstrated a higher immune response against SARS-CoV-2 than mRNA-1273.222, Moderna's licensed COVID-19 vaccine.
In Article Trend: Neutral
March 26, 2024 (15:25) / "CNBC" (by Annika Kim Constantino)
Moderna says new Covid vaccine showed stronger immune response than current shot in study
Moderna's new shot offers the potential of a longer shelf life and is one component of its combination vaccine targeting Covid and the flu.
In Article Trend: Neutral
March 26, 2024 (06:25) / "Benzinga" (by Shanthi Rexaline)
Cathie Wood's Ark Ups Tesla Bet With $28M Stock Buy Amid Rebound, Also Loads Up On This Online Game Platform - Tesla ( NASDAQ:TSLA ) , ARK Innovation ETF ( ARCA:ARKK )
Ark Investment Management, led by Cathie Wood, continued to buy Tesla Inc. TSLA shares on Monday, even though the stock had already rebounded and outperformed the broader market. What Happened: Through its two ETFs, Ark Innovation ETF ARKK and ARK Next Generation Internet ETF ARKW, Ark bought ...
In Article Trend: Somewhat-Bullish
March 25, 2024 (21:00) / "Benzinga" (by Benzinga Insights)
Here's How Much $100 Invested In Moderna 5 Years Ago Would Be Worth Today - Moderna ( NASDAQ:MRNA )
Moderna MRNA has outperformed the market over the past 5 years by 27.27% on an annualized basis producing an average annual return of 40.24%. Currently, Moderna has a market capitalization of $42.31 billion.
In Article Trend: Somewhat-Bullish
March 25, 2024 (20:21) / "Investors Business Daily" (by ED CARSON)
Hot AI Stocks Super Micro, Micron Lead S&P 500
S&P 500: AI Stocks Super Micro, Micron Lead Index Monday Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
March 25, 2024 (13:10) / "Zacks Commentary" (by Zacks Equity Research)
Vertex ( VRTX ) Continues to Diversify Beyond CF Franchise
While CF remains the main area of focus for Vertex Pharmaceuticals (VRTX), it is seeing success in the development of its non-CF pipeline candidates.
In Article Trend: Neutral
March 25, 2024 (11:00) / "Forbes" (by Dmitry Reykhart)
Council Post: What's Driving Big Pharma's Recent Market Performance?
What's Driving Big Pharma's Recent Market Performance? Forbes ...
In Article Trend: Neutral
March 23, 2024 (09:50) / "Motley Fool" (by Keith Speights and Adria Cimino)
A Bull Market Is Here: 2 Magnificent Stocks Down 30% or More to Buy Right Now
These stocks share several things in common.
In Article Trend: Somewhat-Bullish
March 23, 2024 (07:46) / "Motley Fool" (by Adria Cimino)
Artificial Intelligence ( AI ) in Healthcare: 2 Top Stock Picks
These particular healthcare stocks are dirt cheap now considering their AI potential.
In Article Trend: Bullish
March 22, 2024 (19:45) / "Benzinga" (by Benzinga Insights)
Behind the Scenes of Moderna's Latest Options Trends - Moderna ( NASDAQ:MRNA )
Financial giants have made a conspicuous bullish move on Moderna. Our analysis of options history for Moderna MRNA revealed 8 unusual trades. Delving into the details, we found 50% of traders were bullish, while 50% showed bearish tendencies.
In Article Trend: Somewhat-Bullish
March 22, 2024 (16:00) / "PR Newswire" (by Research and Markets)
Vaccine Market Insights Revealed in New 2024 Global Industry Report
DUBLIN, March 22, 2024 /PRNewswire/ -- The "The World Market for Vaccines, 2024" report has been added to ResearchAndMarkets.com's offering. The healthcare landscape is ever-evolving, and as infectious diseases continue to be a global concern, the vaccine market remains a critical area of focus ...
In Article Trend: Somewhat-Bullish
March 21, 2024 (10:00) / "Benzinga" (by Shanthi Rexaline)
Is Cathie Wood Buying The Rumor? Ark More Than Doubles Stake In This COVID-19 Vaccine Maker Ahead Of Flurry Of Catalysts - Moderna ( NASDAQ:MRNA )
Money manager Cathie Wood's Ark Invest has a favorite biotech holding now, going by the firm's recent buying activity. What Happened: Ark, through its flagship Ark Innovation ETF ARKK and Ark Genomic Revolution ETF ARKG, has been brisk with its acquisition of Moderna, Inc. MRNA shares in March.
In Article Trend: Somewhat-Bullish
March 21, 2024 (03:40) / "Benzinga" (by Benzinga Neuro)
Cathie Wood's Ark Invest Sells Another Tranche Of Block Shares, Even As Bitcoin Price Stages A Recovery - Block ( NYSE:SQ )
On Wednesday, Cathie Wood-led Ark Invest made a significant move by offloading shares of Block Inc SQ amidst Bitcoin BTC/USD prices recovering. The sale, worth $3.5 million, was executed through Ark's flagship ARK Innovation ETF ARKK and ARK Next Generation Internet ETF ARKW with a total of ...
In Article Trend: Bullish
March 21, 2024 (01:24) / "Money Control"
Wall Street ends higher as Fed keeps three rate cuts on the horizon
The Fed's policy statement described inflation as remaining "elevated," and it raised economic projections for economic growth and lowered its projection for the unemployment rate from estimates it provided in December.
In Article Trend: Neutral
March 20, 2024 (18:45) / "Motley Fool" (by Motley Fool Transcribing)
BioNTech Se ( BNTX ) Q4 2023 Earnings Call Transcript
BNTX earnings call for the period ending December 31, 2023.
In Article Trend: Somewhat-Bullish
March 20, 2024 (17:07) / "Investors Business Daily" (by Investor's Business Daily)
Is Pfizer Stock, At A Nine-Year Low, A Sell Amid The Search For Its Big Break?
Pfizer ( PFE ) stock is trading at its lowest point in nine years as the drugmaker looks for its next big break after developing the first Covid vaccine with Germany's BioNTech ( BNTX ) . This month, the European Commission approved Pfizer's Prevnar 20, a vaccine to help protect babies and ...
In Article Trend: Neutral
March 20, 2024 (15:49) / "Benzinga" (by Henry Khederian)
Why Moderna Shares Are Falling - Moderna ( NASDAQ:MRNA )
Moderna Inc MRNA shares are trading lower by 2.7% to $102.25 during Wednesday's session in possible sympathy with BioNTech, which reported worse than expected fourth-quarter earnings. In the fourth-quarter of fiscal year 2023 BioNTech SE reported lower earnings and sales than the previous year.
In Article Trend: Neutral
March 20, 2024 (13:09) / "Investors Business Daily" (by Investor's Business Daily)
BioNTech Dives As Sales Crash 65%, Missing Forecasts
BioNTech Stock Dives After Sales Plummet 65% And Miss Forecasts Investor's Business Daily ...
In Article Trend: Neutral
March 20, 2024 (11:44) / "Barrons" (by Brian Swint)
BioNTech Earnings Miss Estimates. The Stock Falls and Also Drags Moderna Lower.
BioNTech Earnings Fall Short of Estimates. The Stock Is Down. ...
In Article Trend: Somewhat-Bearish
March 20, 2024 (04:29) / "Benzinga" (by Benzinga Neuro)
Cathie Wood's Ark Invest Isn't Done Selling Shares Of Jack Dorsey-Led Block Yet - Sheds $7.5M Worth of Stock As Bitcoin Price Drops - Block ( NYSE:SQ )
On Tuesday, Cathie Wood-led Ark Invest offloaded a significant amount of Block Inc SQ shares amidst a downturn in Bitcoin BTC/USD prices. Ark Invest's decision to sell off Block shares came as a surprise to many, given the company's strong ties to the cryptocurrency market.
In Article Trend: Somewhat-Bullish
March 19, 2024 (12:30) / "PR Newswire" (by Flagship Pioneering)
Flagship Pioneering Named to Fast Company's Annual List of the World's Most Innovative Companies of 2024
Ranked #3 Most Innovative Company in North America Recognized for the Third Consecutive Year CAMBRIDGE, Mass., March 19, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, has been named to Fast Company's prestigious list of the World's Most Innovative Companies of ...
In Article Trend: Bullish
March 19, 2024 (05:23) / "Benzinga" (by Benzinga Neuro)
Cathie Wood-Led Ark Invest Sheds Shares Of Jack Dorsey's Block And Coinbase As Bitcoin, Ethereum Take A Breather
On Monday, Cathie Wood-led Ark Invest made significant trades, notably offloading shares of Coinbase Global Inc COIN and Block Inc SQ, despite cryptocurrency market fluctuations. Ark Invest sold 30,458 shares of Coinbase through its flagship ARK Innovation ETF ARKK. The transaction amounted to ...
In Article Trend: Somewhat-Bullish
March 18, 2024 (21:50) / "Zacks Commentary" (by Zacks Equity Research)
Moderna ( MRNA ) Increases Yet Falls Behind Market: What Investors Need to Know
Moderna (MRNA) concluded the recent trading session at $104.26, signifying a +0.39% move from its prior day's close.
In Article Trend: Somewhat-Bullish
March 18, 2024 (14:50) / "Investors Business Daily" (by Investor's Business Daily)
Dow Jones Climbs As Nvidia AI Event Kicks Off; Cathie Wood Snaps Up Stock Amid 51% Plunge
Dow Jones Climbs As Nvidia AI Event Kicks Off. Cathie Wood Snaps Up Stock Amid 51% Plunge Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
March 18, 2024 (10:50) / "Motley Fool" (by Adria Cimino)
Cathie Wood Goes Bargain Hunting: 3 Stocks She Bought Last Week
Wood doesn't worry about short-term share price performance. She bets on the long term.
In Article Trend: Somewhat-Bullish
March 14, 2024 (18:45) / "Benzinga" (by Benzinga Insights)
Peering Into Moderna's Recent Short Interest - Moderna ( NASDAQ:MRNA )
Moderna's MRNA short percent of float has risen 14.95% since its last report. The company recently reported that it has 24.08 million shares sold short, which is 8.38% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.11 days to cover their ...
In Article Trend: Somewhat-Bullish
March 14, 2024 (16:07) / "Zacks Commentary" (by Zacks Equity Research)
Biotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & More
Amylyx Pharmaceuticals (AMLX) and Acadia Pharmaceuticals (ACAD) plunged on failure of studies.
In Article Trend: Neutral
March 14, 2024 (16:00) / "Benzinga" (by Benzinga Insights)
Moderna Unusual Options Activity - Moderna ( NASDAQ:MRNA )
Deep-pocketed investors have adopted a bullish approach towards Moderna MRNA, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.
In Article Trend: Somewhat-Bullish
March 14, 2024 (14:43) / "Zacks Commentary" (by Zacks Equity Research)
Guidewire's ( GWRE ) Cloud Platform Adopted by Trygg-Hansa
Trygg-Hansa Forsakring implements Guidewire's (GWRE) ClaimCenter solution powered by Guidewire Cloud to boost its claims operations.
In Article Trend: Somewhat-Bullish
March 13, 2024 (17:19) / "Investors Business Daily" (by Investor's Business Daily)
Lilly Teams Up With Amazon To Deliver Weight-Loss Drug
Eli Lilly Taps Amazon Pharmacy To Help Deliver Weight-Loss Drug, Zepbound Investor's Business Daily ...
In Article Trend: Neutral
March 13, 2024 (16:04) / "Investors Business Daily" (by ALLISON GATLIN)
IBD Stock Of The Day Lingers In Buy Zone As Diabetes Play Eyes Obesity
Dexcom ( DXCM ) is Wednesday's IBD Stock Of The Day. Dexcom stock is lingering in a buy zone, bolstered by U.S. clearance of a new body-worn glucose monitor. The company developed Stelo, its newest continuous glucose monitor, for the roughly 25 million people in the U.S. with type 2 diabetes ...
In Article Trend: Neutral
March 13, 2024 (16:00) / "Benzinga" (by Benzinga Insights)
$1000 Invested In This Stock 5 Years Ago Would Be Worth $5,000 Today - Moderna ( NASDAQ:MRNA )
Moderna MRNA has outperformed the market over the past 5 years by 27.41% on an annualized basis producing an average annual return of 40.22%. Currently, Moderna has a market capitalization of $42.22 billion.
In Article Trend: Somewhat-Bullish
March 13, 2024 (12:18) / "Benzinga" (by Meg Flippin)
Nanotechnology's Promising Role In Fighting Infectious Diseases: Protecting Surfaces With FendX's Nanotechnology - AstraZeneca ( NASDAQ:AZN ) , FendX Technologies ( OTC:FDXTF )
From therapeutics to new drug delivery systems, nanotechnology can play an important role in fighting infectious diseases. A prime example is evident in the development of the COVID-19 vaccines. During the pandemic, Pfizer Inc. PFE, Moderna Inc. MRNA, Johnson & Johnson JNJ, AstraZeneca Plc.
In Article Trend: Neutral
March 13, 2024 (10:12) / "Motley Fool" (by Adria Cimino and Keith Speights)
Moderna Stock: Bull vs. Bear
This stock delivered spectacular gains in the past.
In Article Trend: Neutral
March 13, 2024 (03:57) / "Benzinga" (by Benzinga Neuro)
Cathie Wood's Ark Invest Keeps Dumping Coinbase Shares Amid Bitcoin, Crypto Buzz - Coinbase Glb ( NASDAQ:COIN )
On Tuesday, Cathie Wood-led Ark Invest made a significant move by offloading a substantial number of shares in Coinbase Global Inc COIN, despite Bitcoin BTC/USD reaching new all-time highs recently.
In Article Trend: Bullish
March 12, 2024 (21:50) / "Zacks Commentary" (by Zacks Equity Research)
Moderna ( MRNA ) Stock Drops Despite Market Gains: Important Facts to Note
Moderna (MRNA) concluded the recent trading session at $110.43, signifying a -1.38% move from its prior day's close.
In Article Trend: Somewhat-Bullish
March 12, 2024 (16:06) / "Zacks Commentary" (by Zacks Equity Research)
Why Moderna ( MRNA ) Stock Price Was Up 9% on Monday
Moderna (MRNA) surges amid initiation reports of a phase II/III study on Merck-partnered experimental cancer therapy to treat patients with cutaneous squamous cell carcinoma, a form of skin cancer.
In Article Trend: Somewhat-Bullish
March 12, 2024 (13:12) / "Investors Business Daily" (by ALLISON GATLIN)
Acadia Plummets After Placebo Effect Torpedoes Schizophrenia Study
Acadia stock crashed to an 11-month low Tuesday after an outsized placebo effect torpedoed the company's efforts to expand Nuplazid to schizophrenia patients. Acadia Pharmaceuticals ( ACAD ) had been hoping its antipsychotic, Nuplazid, would make a difference for people with the negative symptoms ...
In Article Trend: Neutral
March 12, 2024 (12:03) / "Zacks Commentary" (by Zacks Equity Research)
Moderna ( MRNA ) Soars 8.7%: Is Further Upside Left in the Stock?
Moderna (MRNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
In Article Trend: Somewhat-Bullish
March 12, 2024 (11:00) / "Benzinga" (by Shanthi Rexaline)
'Almost Everything Is A Boring Copy:' Tesla CEO Elon Musk Wonders Why There's Hardly Any Innovation After Fan Praises Cybertruck As 'Most Exciting Product Right Now'
Tesla CEO Elon Musk, dubbed the "Renaissance man" and "inventor of our age" by fund manager Cathie Wood, lamented the lack of innovative drive among companies on Monday. What Happened: "There are so few innovative products.
In Article Trend: Somewhat-Bullish
March 11, 2024 (20:10) / "GlobeNewswire" (by CytomX Therapeutics Inc.)
CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update
- CX-904 ( EGFRxCD3 T-cell engager ) initial Phase 1a dose escalation data in solid tumors anticipated in the 2nd half of ...
In Article Trend: Neutral
March 11, 2024 (20:10) / "Benzinga" (by Globe Newswire)
CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update - CytomX Therapeutics ( NASDAQ:CTMX )
- CX-904 ( EGFRxCD3 T-cell engager ) initial Phase 1a dose escalation data in solid tumors anticipated in the 2nd half of 2024 - - CX-2051 ( EpCAM ADC ) Phase 1 clinical study initiation in solid tumors, including colorectal cancer ( CRC ) anticipated in the 1st half of 2024 -
In Article Trend: Neutral
March 11, 2024 (20:10) / "Barrons" (by Barron's Automation)
U.S. Markets Ended Monday Mixed As Moderna Led, Carvana Lagged
U.S. stock indexes ended Monday mixed with the Dow increasing 0.12%. Meanwhile, the S&P 500 Index 0.11%, and the NASDAQ Composite Index declined 0.41%. Small-cap stocks, as per the Russell 2000 Index, dropped 0.82%, while the Cboe Volatility Index was up 3.46%.
In Article Trend: Neutral
March 11, 2024 (18:36) / "Investors Business Daily" (by ALLISON GATLIN)
Moderna Nears First Breakout In A Year As Cancer Vaccine Progresses
Moderna ( MRNA ) stock surged Monday - nearing its first breakout in over a year - after launching a third study of its Merck ( MRK ) -partnered cancer vaccine. The companies will test a combination of the cancer vaccine and Merck's blockbuster cancer drug, Keytruda, in patients with cutaneous ...
In Article Trend: Neutral
March 11, 2024 (18:08) / "Benzinga" (by Vandana Singh)
What's Going On With Moderna Stock On Monday? - Merck & Co ( NYSE:MRK ) , Moderna ( NASDAQ:MRNA )
Recently, on clinicaltrials.gov, Merck & Co Inc MRK posted a new trial of Moderna Inc's MRNA V940, an individualized neoantigen therapy ( INT ) , plus pembrolizumab for locally resectable advanced cutaneous squamous cell carcinoma ( LA cSCC ) .
In Article Trend: Neutral
March 11, 2024 (12:53) / "Motley Fool" (by Alex Carchidi)
1 ( Bad ) Reason to Sell Moderna Stock Right Now, and 2 Good Reasons to Buy It
Sometimes bad news is a bad reason to sell.
In Article Trend: Somewhat-Bullish
March 9, 2024 (13:56) / "Business Insider" (by Sarah May Grunwald)
I've been a tour guide in Rome for 16 years. Here are 9 of the biggest mistakes tourists make.
Mistakes tourists make in Rome, from a tour guide of 16 years - Business Insider ...
In Article Trend: Neutral
March 9, 2024 (06:59) / "Motley Fool" (by Prosper Junior Bakiny)
1 Beaten-Down Stock That's Still Not Worth Buying
For this biotech, a rebound seems far too unlikely.
In Article Trend: Neutral
March 8, 2024 (20:31) / "Benzinga" (by Benzinga Insights)
Market Whales and Their Recent Bets on MRNA Options - Moderna ( NASDAQ:MRNA )
Financial giants have made a conspicuous bullish move on Moderna. Our analysis of options history for Moderna MRNA revealed 13 unusual trades. Delving into the details, we found 53% of traders were bullish, while 46% showed bearish tendencies.
In Article Trend: Somewhat-Bullish
March 7, 2024 (16:31) / "Zacks Commentary" (by Zacks Equity Research)
Why Is Model N ( MODN ) Down 8.3% Since Last Earnings Report?
Model N (MODN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
In Article Trend: Somewhat-Bullish
March 6, 2024 (21:36) / "The Atlantic" (by Jacob Stern)
He Got 49 COVID Shots in One Month!
On June 3, 2021, a roughly 60-year-old man in the riverside city of Magdeburg, Germany, received his first COVID vaccine. He opted for Johnson & Johnson's shot, popular at that point because unlike Pfizer's and Moderna's vaccines, it was one-and-done. But that, evidently, was not what he had in ...
In Article Trend: Neutral
March 6, 2024 (21:20) / "GlobeNewswire" (by Generation Bio Co.)
Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
- Company is leveraging proprietary cell-targeted lipid nanoparticle delivery to develop wholly-owned in vivo program for sickle cell disease and ...
In Article Trend: Neutral
March 6, 2024 (17:08) / "CNBC" (by Annika Kim Constantino)
Healthy Returns: What to know about CDC's new Covid recommendations
The CDC announced two new major Covid recommendations last week. Meanwhile, venture firm General Catalyst said it was buying Summa Health.
In Article Trend: Neutral
March 6, 2024 (11:11) / "CNN" (by Mira Cheng)
A man deliberately got 217 Covid shots. Here's what happened
One German man has redefined "man on a mission." A 62-year-old from Magdeburg deliberately got 217 Covid-19 vaccine shots in the span of 29 months, according to a new study, going against national vaccine recommendations. That's an average of one jab every four days.
In Article Trend: Neutral
March 5, 2024 (20:51) / "CNN" (by Brenda Goodman)
The Covid-19 pandemic killed off one strain of the flu, and that will change the next vaccines
For 10 years, Americans have had access to flu shots that protect against four strains of the virus: two A strains and two B strains. Starting this fall, however, all the flu shots distributed in the United States will contain only three strains, and the change happened in part because of Covid-19.
In Article Trend: Neutral
March 5, 2024 (15:31) / "Associated Press" (by JIM RENDON of The Chronicle of Philanthropy)
Michael Bloomberg tops the Chronicle of Philanthropy's list of America's biggest donors in 2023
Michael Bloomberg, the former New York City mayor, gave the most to charitable causes last year, followed by Nike co-founder Phil Knight and his wife, Penny, and Michael Dell and his wife, Susan, according to the Chronicle of Philanthropy's exclusive list of the 50 Americans who donated the ...
In Article Trend: Somewhat-Bullish
March 5, 2024 (11:19) / "CNN" (by Brenda Goodman)
The Covid-19 pandemic killed off one strain of the flu, and that will change the next vaccines
For 10 years, Americans have had access to flu shots that protect against four strains of the virus: two A strains and two B strains. Starting this fall, however, all the flu shots distributed in the United States will probably contain only three strains, and the change is because of Covid-19.
In Article Trend: Neutral
March 4, 2024 (17:17) / "Benzinga" (by Benzinga Insights)
Unpacking the Latest Options Trading Trends in Moderna - Moderna ( NASDAQ:MRNA )
Financial giants have made a conspicuous bearish move on Moderna. Our analysis of options history for Moderna MRNA revealed 8 unusual trades. Delving into the details, we found 37% of traders were bullish, while 62% showed bearish tendencies.
In Article Trend: Somewhat-Bullish
March 4, 2024 (12:15) / "MarketWatch"
Big losses are pushing venture-backed startups and IPOs over a cliff
Financial backers and firms are both caught in a 'Wile E. Coyote' dilemma, ...
In Article Trend: Neutral
March 4, 2024 (02:33) / "The Financial Express" (by Health Desk)
Oncology innovation thrives in India, despite funding dip of 54.8 percent in India in 2023
In the fast-evolving landscape of the global oncology sector, Tracxn's analysis reveals a narrative of groundbreaking innovation and funding trends.
In Article Trend: Somewhat-Bullish
March 3, 2024 (18:17) / "Motley Fool" (by David Jagielski)
Where Will Moderna Stock Be in 5 Years?
Can Moderna be a good stock to buy if it can no longer count on billions in revenue from its COVID vaccine?
In Article Trend: Neutral
March 3, 2024 (17:45) / "Motley Fool" (by Alex Carchidi)
Is Ginkgo Bioworks Destined to Be in a "Magnificent Seven" of Healthcare Stocks?
It isn't ready for membership today, but it could have a path in the future.
In Article Trend: Somewhat-Bullish
March 3, 2024 (10:45) / "Motley Fool" (by and Neha Chamaria)
5 Top Stocks to Buy in March
This basket of growth, income, and value has a little something for everyone.
In Article Trend: Somewhat-Bullish
March 2, 2024 (18:10) / "Motley Fool" (by Prosper Junior Bakiny)
3 Reasons to Buy Moderna Stock
The company can still deliver excellent returns.
In Article Trend: Neutral
March 2, 2024 (14:30) / "Motley Fool" (by and Prosper Junior Bakiny)
3 Magnificent Growth Stocks to Buy in March
These three stocks have two important common denominators: the same industry and tremendous growth prospects.
In Article Trend: Somewhat-Bullish
March 2, 2024 (10:32) / "Business Insider" (by James Faris)
A partner at $288 billion Baillie Gifford shares 4 simple mistakes that investors consistently make - and 5 under-the-radar stocks with moonshot growth potential
5 Underrated Stocks With Moonshot Potential: Baillie Gifford - Business Insider ...
In Article Trend: Somewhat-Bullish
March 1, 2024 (13:00) / "Motley Fool" (by Marc Rapport)
Got $200? 2 Dividend Stocks to Buy and Hold Forever
Trust these two real estate stocks to be attractively priced and proven performers.
In Article Trend: Somewhat-Bullish
Related stocks from Healthcare sector
Alnylam Pharmaceuticals, Inc. (ALNY)
Invitae Corp. (NVTA)
Novavax, Inc. (NVAX)
Altamira Therapeutics Ltd. (CYTO)
BridgeBio Pharma, Inc. (BBIO)
Palatin Technologies, Inc. (PTN)
Canopy Growth Corp. (CGC)
Creative Medical Technology Holdings, Inc. (CELZ)
Second Sight Medical Products, Inc. (EYES)
Mind Medicine (MindMed) Inc. (MNMD)
This website uses cookies to ensure you get the best experience on our website